Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Endometrial cancer-related marker molecules and their application in the diagnosis of endometrial cancer

An endometrial cancer, diagnosis system technology, applied in the application field of endometrial cancer diagnosis, can solve the problems of difficult screening of patients, low sensitivity, and unpredictable recurrence.

Active Publication Date: 2021-11-23
BEIJING MEDINTELL BIOMED CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] At present, the most commonly used clinical detection markers are sugar chain antigen CA125 and human epididymis protein 4 (HE4). Among them, serum CA125 is helpful for monitoring clinical treatment effect for patients with extrauterine lesions, but for peritoneal inflammation or radiation injury CA125 may be abnormally elevated in patients with isolated vaginal metastases, but CA125 is not elevated in patients with isolated vaginal metastases, so recurrence cannot be predicted in the absence of other clinical findings. In addition, the sensitivity of CA125 and HE4 is low, and it is difficult to effectively screen patient

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Endometrial cancer-related marker molecules and their application in the diagnosis of endometrial cancer
  • Endometrial cancer-related marker molecules and their application in the diagnosis of endometrial cancer
  • Endometrial cancer-related marker molecules and their application in the diagnosis of endometrial cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0072] Example 1 Screening of biomarkers related to endometrial cancer

[0073] 1. Screening method

[0074] (1) The data used for screening and preprocessing methods

[0075]In this example, the data for screening biomarkers related to endometrial cancer were downloaded from the GEO database and the TCGA database respectively, and the public gene expression data and complete clinical Note, among them, the microarray data and clinical information of the GSE17025 dataset were downloaded from the GEO database as a training set, and the sample size was endometrial cancer group: control group = 91:12; the RNA of endometrial cancer was downloaded from the TCGA database- The seq data and clinical information are used as the verification set, and the sample size is endometrial cancer group: control group = 543:35;

[0076] The fastp software double-end sequence automatic detection mode is used to process the raw data; the minimum N base number threshold is 5, the reads minimum leng...

Embodiment 2

[0083] Example 2 Validation and analysis of the diagnostic efficacy of the screened biomarkers

[0084] 1. Verify the analysis method

[0085] The R package "pROC" was used to draw the receiver operating curve (ROC), and the biomarkers CDH1, RPS4X, and CDH1 that were screened in Example 1 and showed significant differential expression between the control group and the endometrial cancer group were analyzed The AUC value, sensitivity, and specificity of +RPS4X were used to judge its diagnostic efficacy for endometrial cancer. Among them, when evaluating and analyzing the diagnostic efficacy of single biomarkers CDH1 and RPS4X for endometrial cancer, the expression level of the gene (Log 2 expression level) for evaluation and analysis, and select the point corresponding to the largest Youden index as its cutoff value, that is, the optimal division threshold is determined by the point with the largest Youden index; in the evaluation and analysis of the combined biomarker CDH1+RP...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
Login to View More

Abstract

The invention discloses endometrial cancer-related marker molecules and their application in the diagnosis of endometrial cancer. The biomarkers are CDH1 and RPS4X, and the combination of CDH1 and RPS4X has better diagnostic efficiency for endometrial cancer. With higher sensitivity and specificity, the present invention also provides a product and a diagnostic system for diagnosing endometrial cancer.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to endometrial cancer-related marker molecules and their application in diagnosing endometrial cancer. Background technique [0002] More than 90% of uterine cancers are endometrial cancers (Endometrial carcinoma, EC), which originate from the epithelium, and most of the remaining uterine cancers are mesenchymal cancers, which originate from the myometrium, and a few are endometrial stromal carcinomas, which account for about 10% of women. 7% of all cancers and a woman's lifetime risk of developing endometrial cancer is 2.5%. EC is one of the three common malignant tumors of the female reproductive system, accounting for 20%-30% of malignant tumors of the female reproductive system. In recent years, the incidence of endometrial cancer has shown a significant upward trend worldwide. And gradually tends to be younger. EC, as a malignant tumor with a high incidence ra...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6886G01N33/574
CPCC12Q1/6886G01N33/57484G01N33/57488G01N33/57442C12Q2600/118C12Q2600/158
Inventor 杨承刚李雨晨刘乐凯
Owner BEIJING MEDINTELL BIOMED CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com